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Background: Pilsicainide, a pure Naþ channel blocker, is a popular antiarrhythmic drug for the man-
agement of atrial tachyarrhythmias (AT), in Japan. However, serious drug-induced proarrhythmias (DIPs)
may unexpectedly occur. We assessed the clinical background of AT patients presenting with DIPs caused
by pilsicainide.
Methods: This study retrospectively enrolled 874 consecutive patients (543 men, 63.6715.3 years old,
and 57.9716.5 kg of body weight), who were orally administered pilsicainide for AT management. We
evaluated the relationship between DIPs and serum pilsicainide concentration, renal dysfunction (esti-
mate glomerular ﬁltration rate, eGFR), and electrocardiogram (ECG) parameters.
Results: Among the patients, 154 (17.6%) had renal dysfunction (eGFRo50 mL/min), including 12 (1.4%)
on hemodialysis. DIPs were present in 10 patients (1.1%): all had renal dysfunction, and one was on
hemodialysis. The eGFR in DIP patients was signiﬁcantly lower than that in the non-DIP patients
(32.2715.1 vs. 68.4722.1 mL/min, po0.001). Among the clinical factors measured, only renal dys-
function (eGFRo50 mL/min) was signiﬁcantly associated with DIPs (OR 44.6; 95% CI 5.61–335.0,
po0.001). Interestingly, among the ECG parameters, the corrected QT (QTc) intervals in DIP patients
were longer than those in non-DIP patients (555.8737.6 vs. 430.7732.6 ms, po0.001). As pilsicainide
concentration increased, both QRS and QTc intervals prolonged. The latter were improved by dis-
continuing pilsicainide administration, and additional treatments.
Conclusions: DIPs caused by pilsicainide administration were strongly associated with renal dysfunction.
Hence, conﬁrmation of renal function would be necessary prior to and/or during the pilsicainide
administration.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pilsicainide has a pure Naþ channel blocking action with slow
recovery pharmacokinetics and, according to the Vaughan Wil-
liams classiﬁcation, is considered an IC antiarrhythmic drug. In
Japan, pilsicainide is a popular antiarrhythmic drug for the man-
agement of atrial tachyarrhythmias (AT), and in particular atrial
ﬁbrillation (AF) [1,2]. Pilsicainide is recognized as safe and easy-to-
use. However, serious drug-induced proarrhythmias (DIPs) may
unexpectedly occur [3,4]. There are only a few well-organized
reports describing the association between DIPs and pilsicainide
administration [3,4].blished by Elsevier B.V. This is an
þ81 3 3768 3620.We assessed the complication rate of DIPs caused by pilsicai-
nide, and the relationship between DIPs and the drug serum
concentration, renal dysfunction, including the estimated glo-
merular ﬁltration rate (eGFR), and 12-lead electrocardiogram
(ECG) parameters, such as the QRS and corrected QT (QTc) inter-
vals after pilsicainide administration.2. Materials and methods
2.1. Study population
This is a retrospective study. Initially, 905 consecutive patients
were enrolled who were orally administered pilsicainide for the
management of ATs such as AF, supraventricular tachycardia (SVT),
and frequent atrial premature contractions (APCs), betweenopen access article under the CC BY-NC-ND license
Table 1
Patients’ characteristics.
Male (%) 543 (62.1)
Age (years) 63.6715.3
Height (cm) 157.7727.2
Weight (kg) 57.9716.5
BMI (kg/m2) 22.773.8
Pilsicainide toxicity (%) 10 (1.1)
Serum Cr (mg/dL) 0.9570.86 (0.83)
eGFR (mL/min) 68.0722.3
eGFRo50 (%) 154 (17.6)
Hemodialysis (%) 12 (1.4)
HT (%) 393 (45.0)
DM (%) 132 (15.1)
DL (%) 196 (22.4)
IHD (%) 112 (12.8)
Stroke (%) 73 (8.4)
CHF (%) 165 (18.9)
Pilsicainide mean dose (mg/day) 89.4744.7
Pill in the pocket (%) 310 (35.5)
Concomitant drugs
β-blocker (%) 170 (19.5)
CCB (%) 171 (19.6)
ARB (%) 275 (31.5)
ACE-I (%) 46 (5.3)
Diuretics (%) 124 (14.2)
Other AADs (%) 113 (12.9)
BMI, body mass index; DM, diabetes mellitus; Cr, creatinine; CKD, chronic
kidney disease; CHF, chronic heart failure; IHD, ischemic heart disease, HT,
hypertension; DL, dyslipidemia lipidemia; CCB, calcium channel blocker;
ARBs, angiotensin receptor blockers; ACE-I, angiotensin-converting enzyme
inhibitor; AAD, antiarrhythmic drug. Data are expressed as the mean7SD,
median, or numbers (%).
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(3.4%) patients whose eGFR was not assessed were excluded; thus,
874 patients were ﬁnally enrolled into the study. Their character-
istics are outlined in Table 1.
2.2. Ethical considerations and Institutional Review Board approval
The study protocol was approved by the Institutional Review
Board (IRB) of the Toho University Medical Center Omori Hospital
(approval number: 27-13), on May 13, 2015. All patients signed an
informed consent form for the study protocol.
2.3. Administration of pilsicainide
Pilsicainide was used continuously or temporarily for the
management of tachyarrhythmias. The administration of pilsicai-
nide commonly started at 75–150 mg/day, and the dosage was
determined by the age, weight, or clinical characteristics of the
patients. In patients who used pilsicainide temporarily, the dosage
begun at 25–100 mg/day. The patients underwent follow-up
reviews every 1–3 months, and the presence of symptoms, phy-
sical examinations, 12-lead ECGs, and blood tests were assessed.
However, patients who received pilsicainide temporarily did not
undergo follow-up reviews, and were examined only once, or a
few times, after the drug administration.
2.4. Deﬁnition of DIP
According to the deﬁnition of DIP due to pilsicainide, the
patients had to meet the following criteria: (1) proarrhythmias,
such as life-threatening arrhythmias (bradycardia or ventricular
tachycardia/ﬁbrillation), were caused by the drug; (2) ECG
abnormalities were not caused by other etiologies; and (3) dis-
continuing the drug and having treatment improved ECGabnormalities. Regarding pilsicainide levels, although the effective
concentration is known, the precise toxic threshold is generally
unclear. The serum concentration of pilsicainide was determined
using high performance liquid chromatography (HPLC).
2.5. Assessment of ECG parameters
The 12-lead ECGs were recorded by electrocardiography (Nihon
Kohden, Tokyo, Japan). The QRS, JT, and QT interval (from the onset
of the QRS complex to the end of the T wave) were measured
automatically. However, we visually assessed whether the para-
meters measured were correct. The QTc interval adjusted the QT
interval correctly by using the Bazett's formula: QTc¼QT/(RR)1/2,
where QTc is the corrected QT interval, QT is the measured QT
interval, and RR is the measured RR interval.
2.6. Statistical analysis
All continuous data were expressed as mean7standard
deviation, medians (quartile: 25–75%), or numbers (expressed as
percentage, %). Comparisons between groups were analyzed using
univariate (unpaired Student's t-test and Fisher's exact test) and
multivariate analyses using a logistic regression model. A p value
of o0.05 was considered statistically signiﬁcant. All statistical
analyses were performed using the R commander software, ver-
sion 1.24 [5].3. Results
3.1. Baseline characteristics
The patients’ mean age was 63.6715.3 years, 543 (62.1%) were
male, and the body mass index (BMI) was 22.773.8 kg/m2. AF
occurred in 677 patients (77.5%), SVT in 87 (10.0%), frequent APCs
in 56 (6.4%), undetermined arrhythmias with palpitations in 10
(1.1%), and other forms of arrhythmia in the remaining 44 patients.
The mean pilsicainide dose administered was 89.4744.7 mg/day,
and 310 patients (35.5%) received pilsicainide temporarily. The
mean eGFR was 68.0722.3 mL/min; 154 patients (17.6%) had an
eGFR of o50 mL/min, and 12 (1.4%) were on hemodialysis. DIPs
were detected in 10 patients (1.1%). These baseline characteristics
are listed in Table 1.
Out of 874 patients administered with pilsicainide, the drug
serum concentration was assessed only in 202 (23.1%). Fig. 1 shows
the distribution of pilsicainide serum concentration according to
the dose administered.
3.2. Risk factors of DIP
In DIP patients, the eGFR was signiﬁcantly lower than that in
non-DIP patients (32.2715.1 vs. 68.4722.1 mL/min, po0.001,
Table 2). Although clinical factors, such as age, renal dysfunction
(eGFRo50 mL/min), use of angiotensin receptor blockers (ARBs),
and diuretics had a signiﬁcant association with DIPs, a multivariate
analysis showed that only renal dysfunction (eGFRo50 mL/min)
was signiﬁcantly associated with DIPs (OR 44.6; 95% CI 5.61–335.0,
po0.001, Tables 2 and 3).
3.3. Characteristics and follow-up of DIP patients
Among the 874 patients, DIPs were observed in 10 (1.1%). All
DIP patients had AF, and they all displayed renal dysfunction. The
pilsicainide serum concentrations were high with only one
exception. The serum potassium level was between 3.1 and
7.2 mM. The 10 DIP patients’ characteristics are listed in Table 4.
Fig. 1. Distribution of the serum concentrations of pilsicainide. Serum pilsicainide
concentrations were plotted against the administrated dose in DIP (black dots) and
non-DIP (white dots) patients.
Table 2
Comparison of the patients’ characteristics between DIP and non-DIP groups.
　 non-DIP (864) DIP (10) p Values
Male (%) 538 (62.3) 5 (50.0) 0.516a
Age (years) 63.4715.3 75.776.7 0.012a
Height (cm) 157.7727.3 154.479.9 0.697b
Weight (kg) 58.0716.6 50.877.2 0.166b
BMI (kg/m2) 22.773.9 21.372.3 0.238b
Cr (mg/dL) 0.9470.83 2.172.1 o0.001b
eGFR (mL/min) 68.4722.1 32.2715.1 o0.001b
Hemodialysis (%) 11 (1.3) 1 (10.0) 0.130a
ARBs (%) 268 (31.0) 7 (70) 0.014a
Diuretics (%) 119 (13.8) 5 (50) 0.007a
BMI, body mass index; ARBs, angiotensin receptor blockers. Data are expressed as
the means7SD or numbers (%).
a The p values were determined by Fisher's exact test.
b The p values were determined by unpaired Student’s t-test.
Table 3
Predictors of DIPs detected by a logistic regression analysis.
Variables Univariable analysis Multivariable analysis
OR (95% CI) p Values OR (95% CI) p Values
Sex 0.61 (0.14–2.66) 0.516 0.82 (0.23–3.00) 0.761
Age475 4.78 (1.12–23.26) 0.016 1.60 (0.42–6.03) 0.823
eGFRo50 44.4 (6.07–1937) o0.001 44.6 (5.61–355) o0.001
ARBs 5.18 (1.17–31.3) 0.014 3.54 (0.89–14.2) 0.074
Diuretics 6.24 (1.41–27.5) 0.007 2.65 (0.72–9.77) 0.143
OR, indicates odds ratio; CI, conﬁdential intervals.
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received by the 10 DIP patients. The ECG ﬁndings revealed that
8 patients lacked P waves, 4 had ventricular tachycardia/ven-
tricular ﬁbrillation (VT/VF), and 6 had bradycardia. All the QRS and
QTc intervals tended to be prolonged. Five patients were treated
with continuous hemodiaﬁltration (CHDF), 2 needed percutaneous
cardiopulmonary support (PCPS), and 4 needed temporary pace-
makers. Table 6 shows the follow-up of DIP patients. One patient
died; the remaining 9 were discharged, as their QRS and QTc
intervals normalized.3.4. Correlation between pilsicainide concentration and ECG
parameters
Regarding the correlation between the ECG parameters in DIP
patients and their pilsicainide blood level, as the drug concentra-
tion increased, both QRS and QTc intervals prolonged (Fig. 2). The
QRS interval in DIP patients was longer than that of non-DIP
patients (223.07135.9 ms vs. 108.2723.6 ms, po0.001). The JT
and QTc intervals in DIP patients was also longer than that in non-
DIP patients (JT; 374.7738.2 ms vs. 322.4728.7 ms, po0.001,
QTc; 555.8737.6 ms vs. 430.7732.6 ms, po0.001). However, the
correlation between the JT interval and the pilsicainide blood
concentration was weak.4. Discussion
4.1. Main ﬁndings
First, 18% of patients had renal dysfunction (eGFRo50 mL/
min), including 1.4% with hemodialysis. The eGFR of DIP patients
was signiﬁcantly lower than that of non-DIP patients, and renal
dysfunction (eGFRo50 mL/min) was the only parameter sig-
niﬁcantly associated with DIPs. Second, as the pilsicainide serum
concentration increased, both QRS and QTc intervals prolonged.
4.2. Pharmacokinetics of pilsicainide
According to the Vaughan–Williams classiﬁcation, pilsicainide
is a class IC antiarrhythmic agent, and it is mostly excreted in the
urine. Therefore, the appropriate dose should be determined with
great care in patients with renal dysfunction, since renal insufﬁ-
ciency would obviously prolong the drug elimination half-life
[6–9]. Although after 0.5 mg/kg pilsicainide administration, the
drug elimination half-life at beta-phase is 5.74 hours (h), in
patients whose creatinine clearance (CCr) is 20–50 mL/min, it
increases to 10 h, and in patients whose CCr is o20 mL/min, it
increases further to 25 h [8,9]. Pilsicainide is a basic drug, and it
binds to serum proteins and in particular to an alpha-1-acid gly-
coprotein [10,11]. Its plasma protein binding ratio is about 27% in
normal subjects, but the ratio has been reported to increase to 37%
in patients with renal dysfunction [6,9,10]. Although the protein
binding ratio elevates in patients with renal dysfunction, the total
concentration of pilsicainide also elevates and, as a result, pilsi-
cainide adverse effects may be induced.
It has been reported that pilsicainide elimination rate is low in
patients on hemodialysis [6,12]. Therefore, these patients have an
increased risk of developing DIP.
4.3. Mechanisms of proarrhythmias associated with pilsicainide
In general, the pilsicainide effective serum concentration is 0.2–
0.9 μg/mL. Although the effective concentration is known, the
precise toxic threshold has not been deﬁned. Torsade de pointes
induced by class IA or III antiarrhythmic drugs is caused by a
prolongation of the QT interval. It is suggested that inhibiting the
Kþ channel current may prolong the repolarization phase and
induce early afterdepolarizations. The proarrhythmic potential of a
particular drug is increased by concomitant electrolyte dis-
turbances, such as hypokalemia or hypomagnesemia. These factors
result in the prolongation of the action potential duration, and
refractoriness at the cellular level [13].
On the other hand, class IC antiarrhythmic drugs inhibit the
Naþ channel current and delay the depolarization, which induces
reentrant ventricular tachycardia based on localized depolariza-
tion disturbances [13,14].
Table 4
Characteristics of patients with DIPs.
No Sex Age
(years)
Height
(cm)
Weight (kg) BMI
(kg/m2)
Rhythm BUN
(mg/dL)
Cr (mg/
dL)
K (mM) PLS concentration
(μg/mL)
Time after administra-
tion (h)
PLS dose
(mg/day)
1 Female 68 142 45 22.3 AF 30 2.03 5.6 5.13 48 150
2 Male 83 158 56 22.4 AF 45 2.44 4.4 2.95 7 50
3 Male 77 161 62 23.9 AFþDDD 44 2.27 4.7 3.7 17 100
4 Female 88 150 46 20.4 AF 42 2.87 7.2 3.91 12 150
5 Female 75 155 53 22.1 AF 64 3.53 6.7 2.32 27 150
6 Male 69 173 59 19.7 AF 40 2.81 4 2.22 2 50
7 Male 76 160 43 16.8 AF 34 2.39 6.8 2.17 24 100
8 Male 67 158 53 21.2 AT 31 7.63 4.7 2.12 120 100
9 Female 80 141 40 20 AF 58 1.65 5.6 1.54 24 100
10 Female 74 145 52 24.7 AFþDDD 21 1.33 3.1 0.26 12 50
BMI, body mass index; AF, atrial ﬁbrillation; DDD, DDD is the type of generic pacemaker code; AT, atrial tachycardia; BUN, blood urea nitrogen; Cr, creatinine; PLS,
pilsicainide; time after administration, time at which PLS concentration was measured, after the administration.
Table 5
ECG ﬁndings and treatment.
No ECG ﬁndings Absent P waves PQ Interval (ms) QRS interval (ms) QTc interval (ms) CHDF PCPS TPM
1 VTþPEA þ – 206 540 þ þ þ
2 VT þ – 196 568 þ  
3 Pacemaker rhythm þ – 600 – þ  
4 Junctional rhythm þ – 188 528 þ  
5 Junctional rhythm þ – 136 552 þ þ þ
6 TdpþVF  212 146 541   
7 Junctional rhythm þ – 234 625   þ
8 Sinus bradycardia  240 202 548   
9 AF bradycardia þ – 160 600   þ
10 VF þ – 162 538   
ECG, electrocardiogram; CHDF, transient hemodiaﬁltration; PCPS, percutaneous cardiopulmonary support; TPM, temporary pacemaker; VT/VF, ventricular tachycardia/
ventricular ﬁbrillation; Tdp, torsades de pointes; AF, atrial ﬁbrillation; PEA, pulseless electric activity.
Table 6
Follow-up of DIP patients.
No Prognosis Rhythm PQ interval (ms) QRS interval (ms) QTc interval (ms) BUN (mg/dL) Cr (mg/dL)
1 Survive Sinus 144 92 422 46 1.02
2 Survive AF – 106 441 36 2.08
3 Survive Sinus 168 134 448 27 1.61
4 Survive AF – 96 445 14 1.09
5 Dead – – – – – –
6 Survive Sinus 184 146 524 – –
7 Survive AF – 90 413 33 1.29
8 Survive Sinus 184 120 440 41 7.85
9 Survive AF – 96 431 14 0.68
10 Survive PM 178 158 502 24 0.59
PM, pacemaker; AF, atrial ﬁbrillation; BUN, blood urea nitrogen; Cr, creatinine.
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cardiac Naþ channels blocking action with slow recovery kinetics
suppresses the transmission of the sinus impulse to the atrium
and prolongs the PQ, and QRS, AH and HV intervals [4].
In our study, the mean serum Kþ concentration of DIP patients
was 5.3 mM, suggesting that this hyperkalemia might have
induced proarrhythmias (Table 4). However, although hyperkale-
mia could be induced by renal dysfunction, the extent at which the
serum Kþ concentration affected DIP patients’ proarrhythmias is
unknown. Other drugs, such as β-blockers or calcium channel
blockers, and other antiarrhythmic drugs (AADs) also have a
proarrhythmic effect, but we failed to observe signiﬁcant differ-
ences in the use of these drugs between DIP and non-DIP patients.
Among DIP patients, two were implanted with a pacemaker
(Table 4, patient nos. 3 and 10). This suggests that the Naþ channel
blocking action of pilsicainide may have been responsible for the
delayed depolarization, therefore causing proarrhythmias in
patients with potential sinus node dysfunction or atrioventricularblock. This is probably because pilsicainide may increase the
depolarization disturbances due to the myocardial dysfunction
caused by heart disease or renal failure, and induce proar-
rhythmias regardless of its serum concentration.4.4. Kþ channel blocking action and pilsicainide
Pilsicainide is a class IC AAD that exerts its action by selectively
blocking Naþ channels, with generally no effect on the Kþ chan-
nels or alpha- or beta-receptors, at clinically relevant concentra-
tions. The pharmacodynamic effects of pilsicainide are character-
ized by slow recovery kinetics, for the onset and offset of its Naþ
channel blocking action [1,8]. Okishige et al. reported the results of
the PSTAF-II study, in which an oral dose of 50 mg of pilsicainide,
administered three times daily increased the QRS interval from 91
ms at baseline to 98 ms, but failed to change the QT interval [15].
Pilsicainide prolongs not only the intra-atrial and proximal His
Fig. 2. ECG parameters and the serum concentration of pilsicainide. As the concentration of pilsicainide increases, both QRS and QTc intervals prolong.
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also the PQ interval [16].
Some case reports demonstrated that a high dose of pilsicai-
nide prolongs the QTc interval, and concomitantly decreases the
heart rate [17]. The authors of the study concluded that the pro-
longation of the QRS interval might contribute to the prolongation
of the QTc interval [17]. However, in basic studies, pilsicainide was
shown to block also the Kþ channels. Pilsicainide blocks the Kþ
channel current in the human ether-a-go-go-related gene (HERG)
with a preferential afﬁnity for the open state of the channel, and
shows a fast access to the binding site [18–20]. As a result, the Kþ
channel blocking action of pilsicainide prolonged the QTc interval
in patients presenting with very high pilsicainide concentrations.
There are some factors responsible for prolonging the QTc
interval in general. In our study, the QTc interval positively cor-
related with the QRS interval, and both intervals prolonged sig-
niﬁcantly. Although there was a weak correlation between the JT
interval and the plasma concentration of pilsicainide, the JT and
QTc intervals in DIP patients were longer than those in non-DIP
patients. Prolonged QTc intervals might be caused not only by a
prolonged QRS interval (secondary effect), but also by high levels
of pilsicainide, blocking Kþ channels (direct effect). Other factors,
such as the serum Kþ concentration and the concomitant use of
other drugs, were not signiﬁcantly associated with the prolonged
QTc interval. Pilsicainide may not only have a Naþ channel
blocking action, but also a Kþ channel blocking action in the high
concentration.
4.5. Preventing DIPs – renal dysfunction and elderly patients
Although there are some reports investigating the administra-
tion of pilsicainide in patients with renal dysfunction, and elderly
patients [6,9,11], the rate of developing acute renal failure or side
effects in those patients remains unknown.
In our study, 18% of the patients had renal dysfunction
(eGFRo50 mL/min) including 1.4% patients on hemodialysis. In
patients whose eGFR was o50 mL/min, the pilsicainide con-
centration was assessed only in 53 (34.4%). DIPs caused by pilsi-
cainide administration were strongly associated with renal dys-
function; therefore, assessing renal function would be necessary
prior to and/or during the administration of pilsicainide. If the
renal function worsens, clinicians should try to reduce the dose or
terminate the administration of pilsicainide while monitoring the
patient general condition, heart rate, and ECG.
Although age was not associated with DIPs, special attention
should be given when administering pilsicainide in elderly
patients. Because these patients are usually administrated withARBs or diuretics, it is likely that their eGFR worsens due to
dehydration or drug-induced renal injury. In our study, the use of
ARBs or diuretics showed a signiﬁcant association with DIPs in the
univariate analysis. Hence, not only the renal function, but also
medications including diuretics, ARBs, and other AADs should be
assessed.
Moreover, it is also important to control the patients’ pilsicai-
nide serum concentration. However, there were cases where,
although pilsicainide serum concentration was in the normal
range, patients still developed DIPs (Table 4, patient no. 10).4.6. Study limitations
This study had some potential limitations: it was a retro-
spective and observational study done in a single institute, and the
number of DIP patients was limited, which may result in a sta-
tistical bias. Further research, possibly with a larger number of
patients, is therefore necessary.5. Conclusions
DIPs caused by pilsicainide were strongly associated with renal
dysfunction, particularly a reduced eGFR. Therefore conﬁrmation
of renal function would be necessary prior to and/or during the
administration of pilsicainide. We should be careful when pre-
scribing pilsicainide in patients whose eGFR is o50 mL/min or in
elderly patients, since their eGFR is more likely to become aggra-
vated (o50 mL/min). ECG parameters, such as the QRS and QTc
intervals could be useful markers to prevent DIPs.Funding and disclosures
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